It’s well-documented that Paxlovid — a 5-day course of antiviral pills from Pfizer — can reduce the risk of hospitalization in COVID-19 patients who are more likely to develop severe illness.
Now, researchers from the Veterans Health Administration find that taking the medication may also reduce the risks of later developing long COVID, according to a new study that was posted online this weekend and has not yet undergone peer review.
“We’ve already known for some time now that Paxlovid reduces the risk of acute problems,” says Dr. Ziyad Al-Aly, chief of research and development at the VA Saint Louis Healthcare System, and co-author of the study, “Now we are adding the observation that Paxlovid also reduces the risk of long COVID.”
The drug, which has been available in the U.S. for almost a year, is provided for free by the federal government at pharmacies across the country. It requires a prescription, and patients with COVID-19 must start it within five days of symptom onset.
Less virus, less long COVID?
In the study, long COVID was defined as developing one or more symptoms — including heart issues, blood disorders, fatigue and trouble breathing — one to three months after testing positive. By these metrics, patients that took Paxlovid were 26% less likely to develop long COVID.
To get to this finding, the researchers combed through electronic health records from more than 56,000 patients in the VA health system who tested positive for COVID-19 between March and June 2022, and had at least one risk factor for severe disease. They compared health outcomes of 9,000 patients that had taken Paxlovid early in their course of illness, with 47,000 patients that had not.
The benefits of taking Paxlovid didn’t just apply to those who were unvaccinated. Patients who were vaccinated or boosted, or had repeat COVID-19 infections, had a similar reduction in the risk of developing long COVID, the study found.
The study is a preprint, meaning it was shared publicly before being reviewed and vetted by outside researchers. But experts who were not involved in the study tell NPR the findings make sense, given how Paxlovid works.
The antiviral drug stops the virus from replicating in cells. “We know that one of the key factors that predict long COVID is detectable virus in the bloodstream at the time of infection,” Dr. Peter Chin-Hong, an infectious disease physician at the University of California, San Francisco, wrote in an email. “So it stands to reason that interventions that prevent the virus from making more copies of itself would therefore lead to a lower risk of long COVID.”
Sponsor Message
Past studies have shown that Paxlovid reduces the risks of hospitalization and death from COVID-19. “Since the trigger of long COVID is acute infection with SARS-CoV-2, it makes intuitive sense that anything that lowers the severity of this infection would reduce the risk of long COVID, whether it’s Paxlovid or other antiviral treatments,” Dr. Paul Sax, an infectious disease physician at Brigham and Women’s Hospital in Boston, wrote in an email.
